Episode Details
Back to Episodes
Apr 02, 2026 | Trump's 100% Drug Tariff Splits Pharma; Lilly Foundayo Approved
Description
Trump signs 100% tariff on imported branded drugs—exemptions create pharma haves and have-nots. Lilly's oral obesity pill Foundayo wins FDA approval as analysts project blockbuster launch. Lilly-Centessa ($6.3B) andBiogen-Apellis ($5.6B) deals cap a $25.5B acquisition spree.
visit us at: www.thepharmacloseout.com
pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Trump pharma tariff, pharmaceutical tariffs, Eli Lilly, Foundayo, orforglipron, FDA approval, obesity drugs, GLP-1, Novo Nordisk, Centessa, Biogen, Apellis, CVR,AstraZeneca, EMERALD-3, liver cancer, Vertex, cystic fibrosis, Alyftrek, Trikafta, EYLEA HD, Regeneron, aflibercept, Lipocine, postpartum depression,Merck, Infinimmune, Blackstone, Ambrosia, M&A, drug pricing, Lilly, AbbVie, GSK, Amgen